PMBS issued low market cap alert (chart)
wallstreetnewscast Newsletter
Wall Street Newscast Traders Newsletter ~~~~~~~~~~~~~~~~~~~~~~~~~~
~~~~~~~~~~~~~~~~~~~~~~~~~~
Ludlow Research Issues Opinion on PMBS Based on Low Market Cap Valuation SCHOFIELD, Wis., April 24, 2013 /PRNewswire via COMTEX/ — PuraMed BioScience�, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research had issued a research opinion on the company and its flagship product, LipiGesic� M.
Report Highlights – Non-Prescription Product to Treat Migraine Headaches – Product Shown to Outperform #1 Prescription Competitor – Holds Patent on Product – Product Currently Available Walgreen`s and CVS/pharmacy stores – Expanding Retail Chain-Store Distribution – Launching Marketing and Distribution Campaign – 34 Million Shares Outstanding PuraMed has contracted both bulk manufacturing and packaging firms to assist in the planned national expansion of LipiGesic M, their over-the-counter migraine relief product. The Company commented that they had selected Hillestad Pharmaceuticals as their fully licensed OTC drug manufacturer, with both Unette Corporation and Proteus Packaging to assist in packaging of products for store shelves. This comes on the heels of news that their over-the-counter migraine pain reliever product was currently in Walgreen`s and CVS/pharmacy stores nationwide, and PuraMed BioScience plans to expand that retail placement to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains.
Current ValuationBased on current and planned distribution to some of the nation`s largest retail drug chains, and having the infrastructure to fulfill orders, PMBS now has all the pieces in place to expand product sales. With just around 34 million common shares outstanding, and a market cap valuation of around $850,000 Ludlow Research feels there could be some good speculative upside potential.
To view the full report, and access risks, disclosures, and potential outlook visit http://www.wallstreetnewscast.com/profile/pmbs.html About PuraMed BioScience, Inc.PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com ~~~~~~~~~~~~~~~~~~~~~~~~~~
About Wall Street Newscast Located in New York City, WallStreetNewscast.com (WSNC) has been providing Wall Street investor presentations for both public and private companies since 1998. WSNC offers a wide-range of services to companies and investor relation professionals to discuss their recent news announcements, earnings reports, and corporate events to a diverse network of individual and institutional investors on Wall Street.www.wallstreetnewscast.com Register online for our free traders newsletter at www.wallstreetnewscast.com/form/newsletter.html ~~~~~~~~~~~~~~~~~~~~~~~~~~
~~~~~~~~~~~~~~~~~~~~~~~~~~
Safe Harbor Statements:
This investor presentation may include statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
Disclaimer:
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC“) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated one thousand dollars for ongoing media coverage. WSNC may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.
~~~~~~~~~~~~~~~~~~~~~~~~~~
Forward this email
Related posts:
- PMBS (.03) on shelves in Walgreens & CVS
- PMBS (.035) going into Walmart & Target
- PMBS already in CVS & Walgreens, 34 mill OS
- PRMK (.029) Q1 Profitable, Midwest Flood Play, Farm Equipment
- $GRST – addiction treatment centers, revs up sharply